Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Targeting the Roots of Cancer
- Cancer Stem Cells 2017

About Confrence


Allied Academics Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies.  This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).

Allied Academics invites all the participants from all over the world to attend "10th International Conference on Cancer Stem Cells and Regenerative Medicine”, on June 26-27, 2017 in London, UK which includes prompt keynote presentations, oral talks, poster presentations and exhibitions.

Cancer stem cells (CSCs) are cancer cells (found within tumors or haematological cancers) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumour-forming), perhaps in contrast to other non-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.

Objective:

Cancer Stem Cells 2017 is a platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Cancer Stem Cells 2017 will have an anticipated participation of 120+ delegates across the world to discuss the conference goal.

About Organizers:

Allied Academics is one of the leading Open Access publishers and organizers of international scientific conferences and events every year across USA, Europe & Asia.  Allied Academics  has so far organized 3000+ Global Allied Academics  Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business with 700+ peer-reviewed open access journals in basic science, health, and technology.

Scientific Sessions:

Cancer Stem Cells 2017 will encompass recent researches and findings in Cancer stem cells technologies, Cancer stem cells therapies and transplantations, current understanding of cell plasticity in cancer and other advancements in Cancer stem cells research and cell science. Cancer Stem Cells 2017 will be a great platform for research scientists and young researchers to share their current findings in this field of applied science. The major scientific sessions in Cancer Stem Cells 2017 will focus on the latest and exciting innovations in prominent areas of Cancer cell science and Cancer stem cells research.

Target Audience:

Eminent personalities, Directors, CEO, President, Vice-president, Organizations, Associations heads and Professors, Research scientists, Cancer Stem Cell laboratory heads, Post-docs, Students other affiliates related to the area of Cancer Stem cells research, Cancer stem cells line companies can be as Target Audience.

 

 

Welcome Message

Allied Academics welcomes all the attendees, speakers, sponsor’s and other research expertise from all over the world to the "10th International Conference on Cancer Stem Cells and Regenerative Medicine” (Cancer Stem Cells-2017) which is going to be held during June 26-27, 2017 in London,UK. We are very much honored to invite you all to exchange and share your views and experience on Caner Stem Cells:Targeting the roots of Cancer-Cancer Stem Cells-2017.

Allied Academics Organizes Cancer Stem Cells-2017 conference along with 300+ Conferences across USA, Europe & Asia every year with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities as editorial board members.

We invite you to join us at the Cancer Stem Cells-2017, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Cancer Stem Cells-2017 organizing committee look forward to meeting you in London, UK.

 

Sessions/Tracks

Allied Academics International Conferences invites all the participants from all over the world to attend 10th International Conference on Cancer Stem Cells and Regenerative Medicine during June 26-27, 2017 at London, UK which includes prompt keynote presentations, oral talks, poster presentations and Exhibitions.


Track-1

Cancer Stem Cells

Cancer stem cells are rare immortal cells within a tumour that can both self-renew by dividing and give rise to many cell types that constitute the tumour, and can therefore form tumors. Such cells have been found in various types of human tumors and might be attractive targets for cancer treatment.

According to this idea, tumors contain:

·Cancer stem cells that divide and feed tumour growth. These cells can self-renew (copy themselves) extensively, and also produce more mature cells called transit amplifying cells.

·Transit amplifying cells that divide a certain number of times then differentiate (or 'mature') into specialized tumour cells.

·Specialized tumour cells that do not divide and so do not contribute to tumour growth.


Track-2

Bio markers of Cancer Stem Cells

Bio marker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition.

In cancer research and medicine, bio markers are used in three primary ways:

·To help diagnose conditions, as in the case of identifying early stage cancers (Diagnostic)

·To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)

·To predict how well a patient will respond to treatment (Predictive).

 

Track-3

Leukaemia Stem Cells

Leukemia is a term used to describe many different kinds of cancers of the blood. However, in all of these, too many white blood cells (also called leukocytes) are produced and these leukemic cells do not mature normally. As a result, they look like immature cells called blasts. These leukemic blasts are not able to perform the functions of normal mature blood cells which is to defend the body against infection and disease.


Track-4

Breast Cancer Stem Cells

Breast cancer stem cells - the first to be identified in a solid tumour - were discovered in 2003 by scientists at the U-M Comprehensive Cancer Center. U-M scientists found that just a few cancer stem cells are responsible for the growth and spread of breast cancer. Unless the cancer stem cells are destroyed, the tumour is likely to come back and spread malignant cells to other parts of the body, a process called metastasis


Track-5

Pancreatic Cancer Stem Cells

Pancreatic cancer stem cells have some similarities to cancer stem cells found in other types of cancer; however, there also appear to be some significant differences. This is why it is important to study the function of these cells in the specific cancer in which these cells arise to best understand their function. Regardless of the organ in which they are found, cancer stem cells appear to be responsible for the propagation of cancer and for its spread to other organs in the body. 


Track-6

Embryonic Stem Cells

Embryonic stem cells (ES cells) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage preimplantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the embryo blast or inner cell mass (ICM) results in destruction of the blastocyst, which raises ethical issues, including whether or not embryos at the pre-implantation stage should be considered to have the same moral or legal status as more developed human beings.


Track-7

Cancer Stem Cells in Brain Gliomas

Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor and contains self-renewing, tumorigenic cancer stem cells (CSCs) that contribute to tumor initiation and therapeutic resistance. As normal stem and progenitor cells participate in tissue development and repair, these developmental programs re-emerge in CSCs to support the development and progressive growth of tumors.


Track-8

Hematopoietic and Chord blood stem cells

Cord blood stem cells are derived from the blood found in the vein of the umbilical cord. Cord blood contains immunologically naïve, hematopoietic stem cells known as HSCs which have been used in medical treatments for 25 years. They are capable of generating the multitude of cell types found in the bloodstream, including red blood cells or erythrocytes; different types of white blood cells, such as lymphocytes and neutrophils; and megakaryocytes which ultimately form platelets.


Track-9

Lung cancer Stem Cells

Lung cancer remains a major cause of cancer-related lethality because of high incidence and recurrence in spite of significant advances in staging and therapies. Recent data indicates that stem cells situated throughout the airways may initiate cancer formation. These putative stem cells maintain protumorigenic characteristics including high proliferative capacity, multipotent differentiation, drug resistance and long lifespan relative to other cells. Stem cell signalling and differentiation pathways are maintained within distinct cancer types, and destabilization of this machinery may participate in maintenance of cancer stem cells. Characterization of lung cancer stem cells is an area of active research and is critical for developing novel therapies. This review summarizes the current knowledge on stem cell signalling pathways and cell markers used to identify the lung cancer stem cells.


Track-10

Prostate Cancer Stem Cells

Prostate Cancer is now a common disease in men over 50 years of age. Medical therapies for prostate cancer are based on discoveries from the mid-twentieth century, and in the long term are rarely curative. Most treatments are directed towards an androgen receptor-expressing, highly proliferative target cell, which does indeed form the vast majority of cells in a prostate tumour. However, by invoking the existence of a cancer stem cell which, like normal epithelial stem cells in the prostate, does not express androgen receptor and is relatively quiescent, the observed resistance to most medical therapies can be explained. The phenotype of the prostate cancer stem cells is that of a basal cell and cultures derived from cancers, but not benign tissues, express a range of prostate cancer-associated RNAs.

 

Track-11

Immune systems in stem cells and cancer

Immuno-oncology is the new and emerging field of cancer research that works to understand the interaction of the immune system with cancers cells and finds ways for harness of the patient’s immune system to treat or prevent cancer. It targets only the immune system, not the cancer cells. Recent advances in our understanding of antigen recognition, presentation and the molecules involved in T and B cell activation have provided new and excited immuno therapeutic strategies which can be used against the cancer cells. Some success in animal models has been observed and some molecules are now being under clinical trials.


Track-12

Molecular medicines for cancers

Molecular medicines for cancers are drugs designed to interfere with specific molecules necessary for tumour growth and progression. Traditional cytotoxic chemo therapies usually kill rapidly dividing cells in the body by interfering with cell division. A primary goal of targeted therapies is to fight cancer cells with more precision and potentially fewer side effects.


Track-13

Clinical research and trials in stem cells and cancer

Cancer research focuses on stem cells present in malignant tumors. Researchers believe current cancer treatments sometimes fail because they don't destroy the cancer stem cells. Think of cancer as a weed: the stem cells are the root while the remaining majority of the cells are the part of the weed above ground. If you remove only the leaves but not the root, the weed will grow back. The same is true for cancer: if you do not kill the cancer stem cells, the cancer is likely to return.


Track-14

Cancer Stem Cells in Solid Tumors

Cancer stem cells (CSCs) are cells that drive tumorigenesis, as well as giving rise to a large population of differentiated progeny that make up the bulk of the tumour, but that lack tumorigenic potential.


Track-15

Epigenetic Identity in Cancer Stem Cells

The Zuotin-related factor 1,ZRF1, has recently been identified as an epigenetic regulator of gene transcription in stem cells and cancer. During differentiation of human teratocarcinoma cells, ZRF1 promotes transcriptional induction of developmental genes that are repressed by Polycomb complexes.


Track-16

Stem Cell Transplantation for Cancer

Stem cell transplant (also called peripheral blood stem cell transplant) is a treatment to try to cure some types of cancer, such as leukemia, lymphoma and myeloma. You have very high doses of chemotherapy, sometimes with whole body radiotherapy. This has a good chance of killing the cancer cells but also kills the stem cells in the bone marrow. Stem cell transplant means that you can have higher doses of treatment. So there may be more chance of curing the cancer than with standard chemotherapy.


Track-17

Regenerative Medicine

Regenerative medicine is a branch of transnational research in tissue engineering and molecular biology which deals with the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function.

 

Track-18

Scaffolds in Regenerative Medicine

Stem cells are self-renewing cells that can be differentiated into other cell types. Conventional in vitro models for studying stem cells differentiation are usually preformed in two-dimensional (2D) cultures. The design of three-dimensional (3D) in vitro models which ideally are supposed to mimic the in vivo stem cells micro environment is potentially useful for inducing stem cell derived tissue formation. Biodegradable scaffolds play an important role in creating a 3D environment to induce tissue formation. The application of scaffolding materials together with stem cell technologies are believed to hold enormous potential for tissue regeneration.


Track-19

Tissue Repair and Regeneration

Tissue Engineering is the investigation of the development of new connective tissues, or organs, from cells and a collagenous platform to create a completely useful organ for implantation over into the contributor host. Effective improvements in the multidisciplinary field of tissue building have created a novel arrangement of tissue new parts and execution approaches. Investigative advances in bio materials, foundation microorganisms, development and separation components, and bio mimetic situations have made special chances to manufacture tissues in the research facility from blends of designed extracellular networks cells, and organically dynamic particles.


Track-20

Cell & Organ Regeneration

Some parts of our bodies can repair themselves quite well after injury, but others don’t repair at all. We certainly can’t regrow a whole leg or arm, but some animals can regrow - or regenerate - whole body parts. Regeneration means the regrowth of a damaged or missing organ part from the remaining tissue. As adults, humans can regenerate some organs, such as the liver. If part of the liver is lost by disease or injury, the liver grows back to its original size, though not its original shape. And our skin is constantly being renewed and repaired. Unfortunately many other human tissues don’t regenerate, and a goal in regenerative medicine is to find ways to kick-start tissue regeneration in the body, or to engineer replacement tissues.


Track-21

Regenerative Medicine Market

Regenerative pharmaceuticals have the one of a kind capacity to repair, supplant and recover tissues and organs, influenced because of some harm, infection. These drugs are ability of restoring the usefulness of cells and tissues. These medications have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, and neurodegenerative sicknesses.

Cell treatment is the quickest developing fragment of regenerative drug. This undeveloped cell treatment is making up the biggest part of this business sector.

 

Track-22

Rejuvenation:

Rejuvenation is a medical discipline focused on the practical reversal of the aging process.

Rejuvenation is distinct from life extension. Life extension strategies often study the causes of aging and try to oppose those causes in order to slow aging. Rejuvenation is the reversal of aging and thus requires a different strategy, namely repair of the damage that is associated with aging or replacement of damaged tissue with new tissue. Rejuvenation can be a means of life extension, but most life extension strategies do not involve rejuvenation.


Track-23

Molecular Mechanisms of Regeneration

There are three major ways by which regeneration can occur. The first mechanism involves the dedifferentiation of adult structures to form an undifferentiated mass of cells that then becomes respecified. This type of regeneration is called epimorphosis and is characteristic of regenerating limbs.


Track-24

Diagnostic & Imaging of Regeneration

In regenerative medicine, clinical imaging is indispensable for characterizing damaged tissue and for measuring the safety and efficacy of therapy. However, the ability to track the fate and function of transplanted cells with current technologies is limited.


Track-25

Bio materials Engineering

A bio material is any matter, surface, or construct that interacts with living systems. As a science, bio materials are about fifty years old. The study of bio materials is called bio materials science or bio materials engineering. It has experienced steady and strong growth over its history, with many companies investing large amounts of money into the development of new products.


Market Analysis Report

Global Market Study of Cancer Stem Cells and Regenerative Medicine:

 

USA: According to a report published by W.H.O cancer fatalities are expected to increase from 14 million in 2012 to 22 million in 2020, 8.2 million deaths worldwide were due to cancer, colorectal cancer constituted 8.4%, breast cancer constituted 6.0% and liver constituted 9.0% in 2012.

 

Europe: Global Cancer stem cell market is expected to grow at a CAGR of 23% for the forecasted period of 2015-2020. Cancer Stem cell research is also being used to study genetic disorders, birth defects and other growth factors.

 

Middle East: Cancer Stem Cell Therapy was conditionally approved in Canada in 2012 .Mesenchymal Stem Cells are purified from the marrow, cultured and packaged, with up to 10,000 doses derived from a single donor. The doses are stored frozen until needed.

 

Asia Pacific: According to a new market research report, ‘Global Cancer Stem Cell Market – Growth, Trends & Forecasts (2015-2020)’, published by Mordor Intelligence, the Global market is expected to be worth US$ 30.25 billion by the end of 2020, The Global market for Stem Cells is expected to grow at a CAGR of 13.7% during the period of (2015-2020).  

Scientific Program
Venue
&
Hospitality
Holiday Inn London - Brentford Lock,Commerce Rd, London TW8 8GA, UK
Join The Discussion

Contact Desk

Drop us an email for Program enquiry

Enquiry

cancerstemcells@alliedconferences.org

+4408000868979

Sponsors/Exhibiting/Advertising

Sponsors

cancerstemcells@alliedconference.com

+4408000868979

Special Issues
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
Press Release
Collaborations

Mail us at

Drop us an email for Program enquiry
cancerstemcells@alliedconferences.org
Sponsors/Exhibiting/Advertising
cancerstemcells@alliedconference.com
General Queries
cancerstemcells@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com

Authorization Policy


Copyright © 2017-2018 Allied Academies, All Rights Reserved.